



**Médecins Sans Frontières/ Doctors Without Borders (MSF)
&
the Drugs for Neglected Diseases initiative (DNDi)**

are pleased to invite you to their following symposium at the MIM 2013

Seasonal Malaria Chemoprevention: a broader picture

Date: Tuesday October 8th, from 5 to 6.30 pm

Place: Hall 4B



Photo: Patients queue in Moïssala District's Bouna health zone, where MSF has been employing seasonal malaria chemoprevention (SMC). Chad 2012 © Estrella Lasry

PROGRAMME 8 October – 17-18.30

SMC: the need, relevance and feasibility of pharmacovigilance.

Prof Alexander Dodoo, Ghana

SMC: Implications for antimalarial drug resistance.

Dr Magatte Ndiaye, Senegal

Malaria prevalence and alternative preventive strategies.

Prof Chris Drakeley, LSHTM, UK

SMC: The experience of MSF- what do we have today and what do we need for tomorrow?

Dr Martin De Smet, MSF, Belgium

Panel - discussion: 30'

Chair: prof Christopher Plowe ,

University of Maryland School of Medicine

Co-chair: Dr Graciela Diap,

Drugs for Neglected Diseases Initiative

Médecins Sans Frontières (MSF) is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, natural disasters and exclusion from healthcare. MSF offers assistance to people based on need, irrespective of race, religion, gender or political affiliation.

MSF has been strongly involved in the improvement of the management of malaria through its investment from the start in the efforts to offer access to ACT's, generalized parasitological diagnosis before treatment and prevention.

MSF focuses currently on the improved management of severe malaria through the use of injectable and rectal artesunate, innovative prevention tools and is involved in the fight against antimalarial resistance.

MSF's teams treated last year in its projects worldwide about 1,5 million malaria patients

For further information about MSF's malaria work, please contact:

Dr Martin De Smet, martin.de.smet@brussels.msf.org

Drugs for Neglected Diseases initiative (DNDi) is an independent not-for-profit research and development organization. Our vision is to improve the quality of life and the health of people suffering from neglected diseases.

Through DNDi 's support innovative and easy-to-use, high quality and affordable fixed-dose combinations of artesunate-amodiaquine and artesunate-mefloquine have been made available

For further information about DNDi's involvement in malaria, please contact:

Dr Graciela Diap, gdiap@ndi.org